Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Antiphospholipid Syndrome Clinical Trials

A listing of Antiphospholipid Syndrome medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (32) clinical trials

Recent-Onset Type 1 Diabetes Trial Evaluating Efficacy and Safety of Teplizumab

This is a Phase 3, randomized, double-blind, placebo-controlled, multinational, multi-center study to evaluate the efficacy and safety of teplizumab, a humanized, anti-CD3 monoclonal antibody, in children and adolescents ages 8 through 17 recently diagnosed with type 1 diabetes (within 6 weeks of diagnosis). Approximately 300 participants will be randomized at ...

Phase

Participation in a Research Registry for Immune Disorders

The purpose of this protocol is to provide a resource for clinical and laboratory research through enrollment of known immunodeficiency patients into a national registry, the US Immunodeficiency Network (USIDNET). The registry data will expand NIH s and the nation s knowledge base about immune deficiency disorders and genetic mutations ...

Phase N/A

A Study of Baricitinib in Participants From 2 Years to Less Than 18 Years Old With Juvenile Idiopathic Arthritis

The reason for this study is to see if the study drug baricitinib given orally is safe and effective in participants with JIA from 2 years to less than 18 years old.

Phase

Eltrombopag vs Standard Front Line Management for Newly Diagnosed Immune Thrombocytopenia (ITP) in Children

This is a prospective, open label, randomized, two-arm, multi-center Phase 3 trial. Patients with newly diagnosed ITP are randomized 2:1 to receive the experimental treatment, eltrombopag, or investigator's choice of 3 standard therapies. The primary objective is to determine if the proportion of patients with platelet response is significantly greater ...

Phase

The Lupus prEGnAnCY Cohort: An International Prospective Cohort of Lupus Pregnancies

Systemic lupus erythematosus (SLE) predominantly affects women during their reproductive years. As SLE is associated with substantial fetal and maternal morbidity during pregnancy and beyond it is crucial to identify predictors of adverse pregnancy outcomes (APO) in SLE to appropriately counsel patients and guide monitoring during pregnancy. SLE pregnancies result ...

Phase N/A

Safety and Tolerability of M254 in Healthy Volunteers and Immune Thrombocytopenic Purpura (ITP) Patients

The Part A of the study is currently not accepting healthy volunteers as the recruitment for the part A has completed.

Phase

Study and Treatment of Inflammatory Muscle Diseases

Polymyositis, dermatomyositis and related disorders, also known as the idiopathic inflammatory myopathies (IIM), are an uncommon, heterogeneous group of diseases. This is an omnibus protocol designed to continue our description of this rare group of diseases, further delineate important groups of patients, and obtain useful material for further study of ...

Phase N/A

Study of Subcutaneous (SC) Belimumab in Pediatric Participants With Systemic Lupus Erythematosus (SLE)

The purpose of this study is to evaluate the pharmacokinetics (PK), safety, and pharmacodynamics (PD) of repeat doses of 200 milligrams per milliliter (mg/mL) belimumab administered via SC injection in pediatric participants 5 to 17 years of age with SLE on a background of standard of care therapy. This bridging ...

Phase

Immune System Related Kidney Disease

Patients with known or suspected immunologically-mediated kidney diseases, including but not limited to, nephrotic syndrome, glomerulonephritis, membranous nephropathy, lupus nephritis, and nephritis associated with other systemic or connective tissue disorders, will be evaluated at the Clinical Center. Patients who have immunologically-mediated diseases with potential for kidney disease will be evaluated ...

Phase N/A

Comparison of Glucose Values and Variability Between TOUJEO and TRESIBA During Continuous Glucose Monitoring in Type 1 Diabetes Patients

The duration of the study per participant will be around 18 weeks :1 or 2 weeks of screening followed by a 4-week run-in period, a 12-week treatment period and a 2 to 4 days follow-up period

Phase